Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America
Author
dc.contributor.author
Cesar, Carina
Author
dc.contributor.author
Shepherd, Bryan E.
Author
dc.contributor.author
Krolewiecki, Alejandro J.
Author
dc.contributor.author
Fink, Valeria I.
Author
dc.contributor.author
Schechter, Mauro
Author
dc.contributor.author
Tuboi, Suely H.
Author
dc.contributor.author
Wolff Reyes, Marcelo
Author
dc.contributor.author
Pape, Jean W.
Author
dc.contributor.author
Leger, Paul
Author
dc.contributor.author
Padgett, Denis
Author
dc.contributor.author
Madero, Juan Sierra
Author
dc.contributor.author
Gotuzzo, Eduardo
Author
dc.contributor.author
Sued, Omar
Author
dc.contributor.author
Mcgowan, Catherine C.
Author
dc.contributor.author
Masys, Daniel R.
Author
dc.contributor.author
Cah
Admission date
dc.date.accessioned
2019-03-11T13:00:07Z
Available date
dc.date.available
2019-03-11T13:00:07Z
Publication date
dc.date.issued
2010
Cita de ítem
dc.identifier.citation
PLoS ONE, Volumen 5, Issue 6, 2018,
Identifier
dc.identifier.issn
19326203
Identifier
dc.identifier.other
10.1371/journal.pone.0010490
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/165040
Abstract
dc.description.abstract
Background: HAART rollout in Latin America and the Caribbean has increased from approximately 210,000 in 2003 to 390,000 patients in 2007, covering 62% (51%-70%) of eligible patients, with considerable variation among countries. No multi-cohort study has examined rates of and reasons for change of initial HAART in this region. Methodology: Antiretroviral-naïve patients≥= 18 years who started HAART between 1996 and 2007 and had at least one follow-up visit from sites in Argentina, Brazil, Chile, Haiti, Honduras, Mexico and Peru were included. Time from HAART initiation to change (stopping or switching any antiretrovirals) was estimated using Kaplan-Meier techniques. Cox proportional hazards modeled the associations between change and demographics, initial regimen, baseline CD4 count, and clinical stage. Principal Findings: Of 5026 HIV-infected patients, 35% were female, median age at HAART initiation was 37 years (interquartile range [IQR], 31-44), and median CD4 count was 105 cells/uL